Preferred Label : Panulisib;
NCIt synonyms : PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170;
NCIt definition : An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target
of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein
kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon
oral administration, panulisib inhibits the activity of all four kinases. This prevents
PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of
cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing
endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of
tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety
of tumors and plays an important role in regulating cancer cell proliferation, growth,
and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type
I receptor family, is overexpressed on endothelial cells in a variety of tumor types
and increases endothelial cell proliferation and migration. DNA-PK is activated upon
DNA damage and plays a key role in repairing double-stranded DNA breaks.;
UNII : S9WA04F921;
InChIKey : VJLRLTSXTLICIR-AUGOTPMTSA-N;
CAS number : 1356033-60-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1356033-60-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : P7170; AK15176;
NCI Metathesaurus CUI : CL445627;
Origin ID : C104292;
UMLS CUI : C5418151;
Semantic type(s)
- concept_is_in_subset
- has_target
